Smith & Nephew ADR Logo
US83175M2052
939163
SNN

Smith & Nephew ADR

Loading quotes...

Forecast

The analysts' average price target is €28.62 (+2.58%). The median is €28.56 (+2.37%).

Buy
  6
Hold
  15
Sell
  2

  • Smith+Nephew Q1 2026: innovation drives growth despite regional divergences

    Smith+Nephew reported revenue of USD 1,501 million for Q1 2026 and organic growth of 3.1%, with favorable currency effects lifting reported growth to 6.6%. Strong performance in Sports Medicine & ENT (+6.7%) and in emerging markets (+10.5%) contrasted with a weak orthopaedics portfolio (+0.8%) and only moderate growth in the US (+2.1%). New products contributed more than half of the growth, the company confirmed its full-year guidance and announced a USD 500 million share buyback program. » More on de.investing.com


  • Smith & Nephew CEO Deepak Nath to become independent non-executive director at Reckitt Benckiser

    Smith & Nephew announced that CEO Deepak Nath will be appointed as an independent non-executive director at Reckitt Benckiser, effective 1 April 2026. Nath will remain in his role as CEO of Smith & Nephew. The announcement was made as part of a required disclosure under UK listing rules and is based on a notice recently filed with the SEC. » More on de.investing.com


  • Moody’s affirms Baa2 for Smith & Nephew and raises outlook to positive

    Moody’s has affirmed Smith & Nephew’s long-term issuer rating at Baa2 and changed the outlook from “stable” to “positive.” The agency cites solid organic revenue and margin growth, improved free cash flow generation and conservative financial policy with a target net leverage of around 2x. Moody’s expects adjusted gross leverage of about 2.3x for 2025 and 2.2x for 2026, and free cash flow after dividends of roughly USD 400m and USD 500m, respectively. An upgrade is possible if the company achieves sustainable organic revenue and EBITDA growth, continued margin expansion, strong free cash flow generation and a gross leverage sustainably below 2.5x. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Smith & Nephew ADR has already paid €0.69 in dividends. The last payout was in November.

Financials

In the last quarter, Smith & Nephew ADR had revenue of €2.72bn and net profit of €265.94m
(EUR) June 2026
YoY
Revenue 2.72bn -
Gross profit 1.93bn -
Net profit 265.94m -
EBITDA 656.52m -

Fundamentals

Metric Value
Market capitalization
€12.14bn
Number of shares
434.54m
52-week high/low
€33.26 - €23.42
Dividend yield
2.49%
Dividends TTM
€0.69
Beta
0.69
P/E ratio
20.40
PEG ratio
0.61
P/B ratio
2.53
P/S ratio
2.03

Company profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Name
Smith & Nephew ADR
CEO
Deepak S. Nath
Headquarters Watford, hrt
United Kingdom
Website
Sector
Industrials
Industry
Commercial Services & Supplies
IPO
08/12/2017
Employees 18,362

Ticker symbols

Exchange Symbol
NYSE
SNN
Frankfurt
NPWA.F
Düsseldorf
NPWA.DU
🍪

Parqet  uses cookies. Learn more